NAVBQ (Navidea Biopharmaceuticals) Cyclically Adjusted Book per Share: $-2.02 (As of Sep. 2023)


NAVBQ Navidea Biopharmaceuticals Inc NAVBQ
16 GF Score
Price $0.00
View Full Analysis

What is Navidea Biopharmaceuticals Cyclically Adjusted Book per Share?

Navidea Biopharmaceuticals NAVBQ 16 Cyclically Adjusted Book per Share is $-2.02 as of Sep. 2023. GuruFocus rates NAVBQ with a GF Score™ of 16/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Navidea Biopharmaceuticals's adjusted book value per share for the three months ended in Sep. 2023 was $-0.033. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-2.02 for the trailing ten years ended in Sep. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-01), Navidea Biopharmaceuticals's current stock price is $0.0001. Navidea Biopharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $-2.02. Navidea Biopharmaceuticals's Cyclically Adjusted PB Ratio of today is .


Navidea Biopharmaceuticals  (OTCPK:NAVBQ) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Navidea Biopharmaceuticals Cyclically Adjusted Book per Share Related Terms


Navidea Biopharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Navidea Biopharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Navidea Biopharmaceuticals Cyclically Adjusted Book per Share Chart

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.67 -1.17 -1.14 -1.63 -1.93

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.93 -1.93 -1.95 -1.96 -2.02

NAVBQ vs PKBO, RSPI, ATRX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Navidea Biopharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navidea Biopharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Navidea Biopharmaceuticals's Cyclically Adjusted PB Ratio falls into.


NAVBQ
16GF Score
Navidea Biopharmaceuticals Inc NAVBQ
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Navidea Biopharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Navidea Biopharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book= Book Value per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.033/307.7890*307.7890
=-0.033

Current CPI (Sep. 2023) = 307.7890.

Navidea Biopharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201312 -0.590 233.049 -0.779
201403 -1.950 236.293 -2.540
201406 -3.164 238.343 -4.086
201409 -4.148 238.031 -5.364
201412 -3.968 234.812 -5.201
201503 -4.760 236.119 -6.205
201506 -5.983 238.638 -7.717
201509 -6.939 237.945 -8.976
201512 -6.978 236.525 -9.080
201603 -7.412 238.132 -9.580
201606 -8.272 241.018 -10.564
201609 -8.249 241.428 -10.516
201612 -8.749 241.432 -11.154
201703 2.786 243.801 3.517
201706 2.056 244.955 2.583
201709 1.892 246.819 2.359
201712 1.403 246.524 1.752
201803 0.525 249.554 0.648
201806 0.259 251.989 0.316
201809 0.148 252.439 0.180
201812 0.174 251.233 0.213
201903 -0.057 254.202 -0.069
201906 0.125 256.143 0.150
201909 -0.042 256.759 -0.050
201912 -0.084 256.974 -0.101
202003 -0.086 258.115 -0.103
202006 -0.096 257.797 -0.115
202009 0.006 260.280 0.007
202012 0.048 260.474 0.057
202103 0.149 264.877 0.173
202106 0.189 271.696 0.214
202109 0.113 274.310 0.127
202112 -0.004 278.802 -0.004
202203 -0.079 287.504 -0.085
202206 -0.149 296.311 -0.155
202209 -0.154 296.808 -0.160
202212 -0.258 296.797 -0.268
202303 -0.300 301.836 -0.306
202306 -0.011 305.109 -0.011
202309 -0.033 307.789 -0.033

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $-2.02 mean?
Navidea Biopharmaceuticals (NAVBQ) has a Cyclically Adjusted Book per Share of $-2.02 as of Sep. 2023. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Navidea Biopharmaceuticals and its competitors.
Is Navidea Biopharmaceuticals' Cyclically Adjusted Book per Share too high?
Navidea Biopharmaceuticals' current Cyclically Adjusted Book per Share is $-2.02. Overall, Navidea Biopharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Navidea Biopharmaceuticals' Cyclically Adjusted Book per Share compare to PKBO and RSPI?
Navidea Biopharmaceuticals' Cyclically Adjusted Book per Share of $-2.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Navidea Biopharmaceuticals and its competitors. Navidea Biopharmaceuticals's current Cyclically Adjusted Book per Share is $-2.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navidea Biopharmaceuticals stock overvalued right now?
Navidea Biopharmaceuticals (NAVBQ) has a current Cyclically Adjusted Book per Share of $-2.02. The current Cyclically Adjusted Book per Share is $-2.02. Navidea Biopharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Navidea Biopharmaceuticals (NAVBQ), the current Cyclically Adjusted Book per Share is $-2.02 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Navidea Biopharmaceuticals Business Description

Address 4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
16GF Score

Get the complete analysis for NAVBQ

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price